Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1

Future Medicinal Chemistry

Volumn 4, Issue 18, 2012, Pages 2311-2323

  Bueno, José M ^a   Herreros, Esperanza ^a   Angulo Barturen, Iñigo ^a   Ferrer, Santiago ^a   Fiandor, José M ^a   Gamo, Francisco J ^a   Gargallo Viola, Domingo ^a   Derimanov, Geo ^b  

^a GLAXOSMITHKLINE   (Spain)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 PHENOXYPHENYL) 4(1H) PYRIDONE; ANTIMALARIAL AGENT; ANTISPOROZOAL AGENT; ATOVAQUONE; CLOPIDOL; DIPYRONE; GSK 932121; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; CROSS RESISTANCE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ELECTRON TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MYXOGASTRIA; NONHUMAN; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; TOXICOLOGY;

ANIMALS; ANTIMALARIALS; ELECTRON TRANSPORT COMPLEX III; HUMANS; MALARIA; MALARIA, FALCIPARUM; PLASMODIUM; PLASMODIUM FALCIPARUM; PYRIDONES;

EID: 84871065409     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.177     Document Type: Review

References (47)

1. Wells TN, Poll EM. When is enough enough? The need for a robust pipeline of high-quality antimalarials. Discov. Med. 9, 389-398 (2010).
2. Olliaro P, Wells TN. The global portfolio of new antimalarial medicines under development. Clin. Pharm. Ther. 85(6), 584-595 (2009).
3. Dondorp AM, Yeung S, White L et al. Artemisinin resistence: current status and scenarios for containment. Nat. Rev. Microbiol. 8, 272-280 (2010).
4. Slichtzer M, Ortmann R. Feeding the antimalarial pipeline. ChemMedChem 5, 1837-1840 (2010).
5. Burrows JN, Waterson D. Discovering new medicines to control and eradicate malaria. In: Third World Diseases: Topics in Medicinal Chemistry, Vol. 7. Elliott RL (Ed.). Springer-Verlag, Berlin-Heidelberg, Germany, 125-180 (2011).
6. Rodrigues T, Lopes F, Moreira R. Inhibitors of the mitochondrial electron transport chain and the novo pyrimidine biosynthesis as antimalarials: the present status. Curr. Med. Chem. 17, 929-956 (2010).
7. Mather MW, Henry KW, Vaidya AB. Mitochondrial drug targets in apicomplexan parasites. Curr. Drug Targets 8, 49-60 (2007). (Pubitemid 46043898)
8. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446, 88-91 (2007). (Pubitemid 46348043)
9. Mi-Ichi F, Takeo S, Takashima E et al. Unique properties of respiratory chain in Plasmodium falciparum mitochondria. Adv. Exp. Med. Biol. 531, 117-133 (2003). (Pubitemid 37034443)
10. Gardner MJ, Hall N, Fung E et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
11. Kessl JJ, Meshnick S, Trumpower BL et al. Molecular basis for atovaquone binding to the cytochrome bc1 complex. J. Biol. Chem. 278, 31312-31318 (2003). (Pubitemid 36994650)
12. Vaidya AB, Mather MW. Atovaquone resistance in malaria parasites. Drug Resist. Updat. 3(5), 283-287 (2000).
13. Fivelman Q, Butcher G, Adagu I, Warhurst D, Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malaria J. 1(1), 1-4 (2002). (Pubitemid 38957422)
14. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. malarone clinical trials study group. Am. J. Trop. Med. Hyg. 60, 533-541 (1999). (Pubitemid 29233107)
15. Nam TG, Vaidya AB, Winzeler EA et al. A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem. Biol. 6(11), 1214-1222 (2011).
16. Cross RM, Namelikonda NK, Mutka TS, Luong L, Kyle DE, Manestch R. Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones. J. Med. Chem. 54 (24), 8321-8327 (2011).
17. Winter R, Kelly JX, Smilkstein MJ, Hinrichs D, Koop DR, Riscoe MK. Optimization of endochin-like quinolones for antimalarial activity. Exper. Parasitol. 127(2), 545-551 (2011).
18. Valiéres C, Fisher N, Antoine T et al. HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex. Antimicrob. Agents Chemother. 56(7), 3739-3747 (2012).
19. Biagini GA, Fisher N, Shone AE et al. Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proc. Natl Act. Sci. USA 109(21), 8298-8303 (2012).
20. Dong DK, Urgaonkar S, Cortese JF et al. Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. Chem. Biol. 18(12), 1602-1610 (2011).
21. da Cruz FP, Martin C, Bucholz K et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J. Infect. Dis. 205(8), 1278-1286 (2012).
22. Markley LD, Van Heertum JC, Dooreubos HE et al. Antimalarial activity of clopidol, 3,5-dichloro-2,6-dimethyl-4-pyridinol, and its esters, carbonates, and sulfonates. J. Med. Chem. 15, 1188-1189 (1972).
23. Fry M, Williams RB. Effects of decoquinate and clopidol on electron transport in mitochondria of eimeria tenella (apicomplexa: coccidia). Biochem. Pharmacol. 33, 229-240 (1984). (Pubitemid 14191050)
24. Markley LD, Eckman M. Synthesis and anticoccidial activity of 3-fluoro-5-chloro and bromo-2,6-dimethyl-4-piridinol. J. Med. Chem. 16, 297-298 (1973).
25. Yeates CL, Batchelor J, Bueno JM et al. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J. Med. Chem. 51, 2845-2852 (2008). (Pubitemid 351620805)
26. Steck EA. Chemotherapy of Malaria. Division of Medicinal Chemistry, Walter Reed Army Institute of Research, US Government Printing Office, Washington DC, USA (1972).
27. Wiselogle FY. A survey of antimalarial drugs 1941-1945. Edwards JW (Ed.). Ann Harbor, MI, USA, 1-1921 (1946).
28. Desjardins R E, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16, 710-718 (1979). (Pubitemid 10082023)
29. Hassan AM, Björkman A, Landberg-Lindgren A, Ashton M. The effect of artemisinin, its derivatives and mefloquine against chloroquine-resistant strains of Plasmodium falciparum in vitro. Trans. R. Soc. Trop. Med. Hyg. 86(4), 365-367 (1992).
30. Hez-Deroubaix S, Bentchikou E, Blanc C, Gripon P, Belghiti J et al. Strong anti-liver stage activity of a novel 4(1H)-pyridone antimalarial compound. Program and Abstracts of the 54th Annual Meeting of the ASTMH. Am. J. Trop. Med. Hyg. 73(Suppl. 6), 30 (2005).
31. Pudney M, Yeates C, Pearce J, Jones L, Fry M. New 4-pyridone antimalarials which potentiate the activity of atovaquone (566C80). Abstracts and Programme Vol 2, Proceedings of the 13th International Congress for Tropical Medicine and Malaria, Pattaya, Thailand, Nov 29-Dec 4, 149 (1992).
32. Xiang H, Surdy-Freed J, Subbanagounder G et al. Preclinical pharmacokinetics and metabolism of GW308678, a second generation 4(1H)-pyridone anti-malarial mitochondrial electron transport inhibitor. Program and Abstracts of the 55th Annual Meeting of the ASTMH. Am. J. Trop. Med. Hyg. 75(Suppl. 5), 248 (2006
33. Xiang H, Surdy-Freed J, Ferrer S et al. Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor. J. Pharm. Sci. 95, 2657-2672 (2006 (Pubitemid 46093173)
34. Butler J, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J. Pharm. Sci. 99(12), 4940-4954 (2010).
35. Valkó K, Du DM, Bevan Ch, Reynolds DP, Abraham MH. Rapid method for the estimation of octanol/water partition coefficient (logpoct) from gradient RP-HPLC retention and hydrogen bond acidity term (sigma alpha2H). Curr. Med. Chem. 8(9), 1137-1146 (2001). (Pubitemid 32633663)
36. Dressman JB, Reppas Ch. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 11(Suppl. 2), S73 (2000).
37. Bueno JM, Manzano P, García Chicharro J et al. Potent antimalarial 4-pyridones with improved physicochemical properties. Bioorg. Med. Chem. Lett. 21, 5214-5218 (2011).
38. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97(2), 539-547 (2007). (Pubitemid 47073868)
39. Jiménez-Díaz MB, Mulet Y, Angulo-Barturen I et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob. Agents. Chemother. 53(10), 4533-4536 (2009).
40. Müller RH, Jacobs D, Kayser O. nanosuspensions as particulate drug formulations in therapy. rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19 (2001). (Pubitemid 32209229)
41. Heimbach T, Fleisher D, Kaddoumi A. overcoming poor aqueous solubility of drugs by oral delivery. In: Prodrugs: Challenges and Rewards, Part 1. Springer, New York, NY, USA, 157 (2007).
42. Becker S, Thornton L. Fosamprenavir: Advancing HIV protease inhibitor treatment options. Expert Opin. Pharmacother. 5, 1995-2005 (2004). (Pubitemid 39236600)
43. Saari WS, Schwering JE, Lyle P, Smith SJ, Engelhardt EL. Cyclization-activated prodrugs. basic carbamates of 4-hydroxyanisole. J. Med. Chem. 33, 97-101 (1990). (Pubitemid 20038176)
44. Kearney AS, Stella VJ. Hydrolysis of pharmaceutically relevant phosphate monoester monoanions: correlation to an established structure-reactivity relationships. J. Pharm. Sci. 82, 69-72 (1993). (Pubitemid 23148853)
45. Furfine ES, Baker CT, Hale MR et al. A preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48, 791-798 (2004). (Pubitemid 38280326)
46. McComb RB, Bowers GNJ, Posen S. Alkaline Phosphatase. Plenum Press, New York, USA and London, UK (1979).
47. Barton V, Fisher N, Biagini GA, Ward SA, O'Neill PM. Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr. Opin. Chem. Biol. 14(4), 440-446 (2010).